A biopharmaceutical company is looking for ways to slim down household pets.

Okava Pharmaceuticals, a San Francisco based company, plans to introduce on Tuesday a new GLP-1 clinical weight loss study for cats.

MEOW-1, as the study is called, will look to use OKV-119, a miniature implant, in cats which will deliver the GLP-1, continuously for up to six months.

According to Okava, MEOW-1 is the first-ever weight loss trial using this approach on household pets.

The study will examine up to 50 cats who will take the implant and have their weight studied at three months on the drug, though the cats will remain under evaluation for six months, according to Okava CEO Michael Klotsman.

Klotsman said the goal would be to file for FDA approval for the product between 2027 and 2028, and the

See Full Page